In the Journals

Yoga may be ‘game changer’ for patients with migraine

May 13, 2020
Yoga as an add-on therapy was superior to medical therapy alone for adults with migraine, according to a prospective, randomized, open-label trial…
In the Journals

Survey raises question about Botox protocol for migraine prevention

May 4, 2020
More than two-thirds of headache medicine clinicians who were surveyed reported altering the standardized protocol for injecting Botox, or…

Real-world data show erenumab prevents migraine attacks, reduces intensity

April 23, 2020
New real-world data show a monthly self-injection of erenumab, a preventive migraine treatment, reduced migraine intensity and the incidence of…

American Headache Society collaborates with PCPs to improve migraine care

April 22, 2020
A new advisory board commissioned by the American Headache Society is developing strategies to improve migraine care in primary care offices. The…

Migraine drug to be tested as potential treatment for COVID-19-related lung inflammation

April 22, 2020
Intranasal vazegepant, a calcitonin gene-related peptide receptor agonist currently in phase 3 development for the treatment of acute migraine, will…

AXS-07 effective against migraine pain in phase 3 INTERCEPT trial

April 16, 2020
Results of the phase 3 INTERCEPT trial showed that AXS-07, an oral agent for acute migraine treatment, was significantly more effective at preventing…
In the JournalsPerspective

Study shows long-term efficacy of erenumab for chronic migraine

April 8, 2020
A 52-week open label extension of a previous 12-week double-blind treatment study showed sustained efficacy and safety of erenumab for the treatment…
In the Journals

PPE-associated headaches increase among health care workers amid COVID-19

April 7, 2020
Prolonged use of personal protective equipment during the COVID-19 pandemic such as N95 masks and protective eyewear was shown to cause or exacerbate…

Biohaven advances intranasal vazegepant for acute migraine

March 27, 2020
After a successful end-of-phase 2 meeting with the FDA, Biohaven Pharmaceuticals announced in a press release that intranasal vazegepant, a novel…
Feature

Q&A: New tool may help guide drug development for pediatric migraine

March 25, 2020
A new FDA-funded registry developed by researchers at the Duke Clinical Research Institute and partners could help answer important questions about…